Applying the same analyses to HER2- cells reveals that the relationship between expression of the three genes and pathway dependence is specific to HER2+ cancers; only AKT1 comes up as differentially sensitive target using the three biomarker combination, while PIK3CA, MTOR and MAPK1 do not, as in the HER2+ population. Here, AKT1 is linked to cancer.